Compare Merck & Co., Inc. (MRK) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Snap On Incorporated — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while Snap On Incorporated trades at $402.3 (market cap $21.06B). The key difference: Merck & Co., Inc. is far larger — about 14.6× Snap On Incorporated's market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MRK | SNA | |
|---|---|---|
Market Cap | $307.25B | $21.06B |
Sector | Health | Technology |
52-Week High | $129.52 | $414.97 |
52-Week Low | $77.60 | $317.79 |
Enterprise Value | $350.66B | $20.58B |
Dividend Yield | 2.73% | 2.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Snap-on Incorporated (SNA) trades at $406.53, down 1.09% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $407.50. The company reported strong 2025 results with $5.16B revenue and $1.02B net income, maintaining robust profitability margins. Recent strategic acquisitions like Diesel Laptops for $100M aim to expand its heavy-duty diagnostics capabilities, supporting future growth.
The outlook is positive given solid fundamentals and analyst support, but risks include potential margin pressures and reliance on automotive demand. With 64.71% of analysts rating it a buy and a dividend yield supported by recent declarations, SNA presents a stable investment opportunity tempered by industry cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
